Backs FY23 revenue view $351.5B-$357.3B, consensus $353.74B. Backs FY23 adjusted operating income view $17.2B-$17.6B. “By broadening our portfolio of integrated products and services, we expect to create a path to sustainable, profitable growth,” Cowhey said. “Our powerful cash generation capabilities will support our strategic goals, prudent capital deployment, and attractive return profile – while also providing opportunities for meaningful long-term outperformance.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer
- CVS Health to hold investor day
- 3 Best Stocks to Buy Now, 11/22/2023, According to Top Analysts
- Foot Locker, Teamsters drop drug-benefit managers over costs, WSJ says
- Pharmageddon Post-Mortem: CVS (NYSE:CVS), Walgreens (NASDAQ:WBA) Unconcerned
